Stephanie Wang is an of counsel at Global Law Office. Stephanie Wang is deep-dived in Life Sciences & Healthcare industry, and mainly focuses practice areas in M&A, cross-boarder license deal, private equity investment, compliance & risk control and capital markets. She routinely counsels clients from leading pharmaceutical companies on various general corporate and transaction matters, clients including GSK, Roche, Siemens, Zeiss, Abbott, Ipsen, Shanghai Pharmaceuticals, Viatris, CanSino, BriiBio, Hanhui Pharma, Alphamab Oncology, WEGO Group, Jemincare, etc. Stephanie Wang provides relevant legal services in the field of enterprise compliance and risk control business, including enterprise compliance risk assessment, establishment and improvement of compliance system and policy.

Stephanie Wang has worked in the legal department of a notable pharmaceutical company in China handling general corporate related matters during her secondment.

Stephanie Wang has also been worked with notable PE institutions providing legal services on legal due diligence, planning of transaction structure, drafting and negotiation of investment agreements and closing services of investment projects. Stephanie Wang has been involved in several projects of IPO, listing companies’ major assets restructure transactions, M&A, refinancing and ESOP. She has rich experiences in asset deals and reform of mixed ownership of SOEs and the acquisition of non-performing assets projects.

Stephanie joined Global Law Office in 2021. Prior to joining Global, Stephanie worked in a notable domestic law firm in the areas of securities, M&A, PE investment, assets management and FDI.

Admitted in the PRC (2016)

LL.B., Hunan University (2009)

LL.M., Queen Mary, University of London (2011)

• 2023 Chambers, Life Sciences: China Law & Practice
• 2023 Official WeChat Account of Global Law Office, Interpreting the Measures for the Administration of Internet Advertising from the Perspective of Life Sciences
• 2023 Official WeChat Account of Global Law Office, Compliance Review of the Policies on the Importation of Pharmaceuticals and Medical Devices from Hong Kong and Macao to the GBA Area for Urgent Clinical Needs (Episode 2)
• 2023 Wolters Kluwer, Year-end Review of Policies and Compliance Supervision and Administration in the Field of Life Sciences and Healthcare in 2022
• 2022 Wolters Kluwer, Targeting the Legal Risks and the Resolutions  in the Pharmaceutical Licensing Deals
• 2022 Official WeChat Account of Global Law Office, Data Compliance in Pharmaceutical Clinical Trials - Episode 2: Discussion on Practical Issues of Processing Personal Information of Trial Subjects